Home | Welcome to Contract Pharma   
Last Updated Thursday, May 28 2015


Financial Report: Wockhardt

Published October 25, 2013
2Q Revenues: 12.0 billion rupees (-11%)

2Q Earnings: 1.4 billion rupees (-70%)

YTD Revenues: 26.0 billion rupees (-5%)

YTD Earnings: 4.6 billion rupees (-44%)

Comments: Results were impacted by restrictions on shipping medicines to the U.S. and UK from one of its factories after health regulators identified deficiencies at the plant. The UK’s MHRA recently added restrictions on exports from two other factories. According to a Wockhardt statement, the U.S. import alert, reported in May, could cost about $100 million in annual sales. It has subsequently taken measures to improve quality oversight at its factories, including the appointment of a new quality chief and hiring of outside consultants.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On